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management patterns In acute CORonary syndrome patients (EPICOR) registry
(NCT01171404), a prospective, observational study conducted in Europe and Latin
America, which enrolled ACS survivors at discharge. Antithrombotic management
patterns, mortality, a composite endpoint of death/new non-fatal myocardial
infarction/stroke, and bleeding events were assessed after 2-years of follow-up in
patients ±AF.
Results: Of 10,568 patients enrolled, 397 (4.7%) had prior AF and 382 (3.6%) new-
onset AF during index hospitalization. Fewer patients with AF underwent PCI (52.1%
vs. 66.6%, p < 0.0001). At discharge, fewer AF patients received DAPT (71.6% vs.
89.5%, p < 0.0001); oral anticoagulant (OAC) use was higher in AF patients but still
infrequent (35.0% vs. 2.5%, p < 0.0001). Use of DAPT and OAC declined over follow-
up with >50% of all AF/no-AF patients remaining on DAPT (55.6% vs. 60.6%), and
23.3% (new-onset AF) to 42.1% (prior AF) on OAC at 2-years. At 2-years, mortality,
composite endpoint and bleeding rates were higher in AF patients (all p < 0.0001) as
compared to patients without AF. On multivariable analysis, risk of mortality or
composite endpoint was significant for prior AF (p = 0.003, p = 0.001) but not new-
onset AF (p = 0.88, p = 0.92).
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Conclusions: ACS patients with AF represent a high-risk group with increased event
rates during long-term follow-up. Prior AF is an independent predictor of mortality
and/or ischaemic events at 2-years. Use of anticoagulants in AF after ACS is still
suboptimal.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Manuscript ref: ACC-D-17-00211R1 
 
Uwe Zeymer, MD 
Klinikum Ludwigshafen and Institut für Herzinfarktforschung Ludwigshafen 
Bremserstrasse 79 
67063 Ludwigshafen 
Germany 
Tel: +49 621 503 2941 
Fax: +49 621 503 4044 
Email: zeymeru@klilu.de 
 
                               22th February 2018 
Dear Dr Vrints / Editor-in-Chief 
European Heart Journal: Acute Cardiovascular Care 
On behalf of all authors, and in response to your invitation of February 12, 2018, I am 
pleased to submit this revised article entitled, ‘Impact of known or new-onset atrial 
fibrillation on 2-year cardiovascular event rate in patients with acute coronary 
syndromes: results from the prospective EPICOR Registry’, to be considered for 
publication in European Heart Journal: Acute Cardiovascular Care. We have found the 
Editor’s and Reviewers comments very helpful and our detailed responses to each specific 
point are shown in bold below. 
 
Reviewer’s Comments 
Reviewer #2 
 Reviewer #2: After the revision, the manuscript has improved.  
 
There are still some parts that needs language editing [eg. in the abstract: At 2-years, mortality, 
composite endpoint and bleeding rates were higher in AF patients (all p < 0.0001)] should be followed 
by "as compared with patients without AF.  
 
Response: done   
 
Finally, a composite endpoint is not the sum of the components but rather the first occurrence of any 
of the components. This is why the correct wording logic is OR, not AND. A simple demonstration is 
exactly in Figure 2: the composite rate is always lower than the sum of the individual components (eg. 
prior AF composite rate at 2 yrs is 18.7% but the sum of the components is 15.1 +3.2 + 1.0= 19.3). 
Another hint is that in every RCT that used this composite endpoint reported in the NEJM trial (CURE, 
TRITON, PEGASUS, PLATO, TRACER, TRA2P, all CHAMPION trials, etc) the wording logic in the 
abstract is always death, MI, OR stroke. Therefore I invite the author to reconsider their 
disagreement.   
 
Resonse: We agree and have changed the wording accordingly to or throughout the 
manuscript.  
 
The authors again thank the reviewers for their thorough review. I can confirm all listed 
authors have contributed and approved this revised version. 
 
We look forward to hearing from you. 
Response to review
Manuscript ref: ACC-D-17-00211R1 
 
 
 Yours Sincerely 
 
 
 Uwe Zeymer 
 
Impact of known or new-onset atrial fibrillation on 2-year 
cardiovascular event rate in patients with acute coronary 
syndromes: results from the prospective EPICOR Registry 
IIUwe Zeymer1, IILieven Annemans2, IINicolas Danchin3, IIStuart Pocock4 IISimon 
Newsome4, IIFrans Van de Werf5, IIJesús Medina6, IIHéctor Bueno7,8,9 
1Klinikum Ludwigshafen and Institut für Herzinfarktforschung Ludwigshafen, 
Ludwigshafen, Germany; 2I-CHER Interuniversity Centre for Health Economics 
Research UGent, VUB, Belgium; 3Hôpital Européen Georges Pompidou, and René 
Descartes University, Paris, France; 4London School of Hygiene and Tropical 
Medicine, London, UK; 5Department of Cardiovascular Sciences, University of 
Leuven, Belgium; 6Medical Evidence and Observational Research, Global Medical 
Affairs, AstraZeneca, Madrid, Spain; 7Centro Nacional de Investigaciones 
Cardiovasculares, Madrid, Spain; 8Instituto de Investigación i+12 and Cardiology 
Department, Hospital Universitario 12 de Octubre, Madrid, Spain; 9Universidad 
Complutense de Madrid, Spain 
Corresponding author: Uwe Zeymer, Klinikum Ludwigshafen and Institut für 
Herzinfarktforschung Ludwigshafen, Bremserstrasse 79, 67063 Ludwigshafen, 
Germany. 
Tel: +49 621 503 2941; Fax: +49 621 503 4044; Email: zeymeru@klilu.de  
IIThis author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and 
their discussed interpretation. 
Total word count: 3316 excluding references and tables/figures 
Manuscript (include Title page, Abstract and References)
2 
Abstract 
Background: Atrial fibrillation (AF) is associated with increased morbidity in acute 
coronary syndromes (ACS) patients, but impact on outcomes beyond 1-year is 
unclear. 
Methods: This was a post-hoc analysis from the long-tErm follow-uP of 
antithrombotic management patterns In acute CORonary syndrome patients 
(EPICOR) registry (NCT01171404), a prospective, observational study conducted in 
Europe and Latin America, which enrolled ACS survivors at discharge. 
Antithrombotic management patterns, mortality, a composite endpoint of death/new 
non-fatal myocardial infarction/stroke, and bleeding events were assessed after 2-
years of follow-up in patients ±AF.  
Results: Of 10,568 patients enrolled, 397 (4.7%) had prior AF and 382 (3.6%) new-
onset AF during index hospitalization. Fewer patients with AF underwent PCI (52.1% 
vs. 66.6%, p < 0.0001). At discharge, fewer AF patients received DAPT (71.6% vs. 
89.5%, p < 0.0001); oral anticoagulant (OAC) use was higher in AF patients but still 
infrequent (35.0% vs. 2.5%, p < 0.0001). Use of DAPT and OAC declined over 
follow-up with >50% of all AF/no-AF patients remaining on DAPT (55.6% vs. 60.6%), 
and 23.3% (new-onset AF) to 42.1% (prior AF) on OAC at 2-years. At 2-years, 
mortality, composite endpoint and bleeding rates were higher in AF patients (all p < 
0.0001) as compared to patients without AF. On multivariable analysis, risk of 
mortality or composite endpoint was significant for prior AF (p = 0.003, p = 0.001) but 
not new-onset AF (p = 0.88, p = 0.92). 
Conclusions: ACS patients with AF represent a high-risk group with increased 
event rates during long-term follow-up. Prior AF is an independent predictor of 
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mortality and/or ischaemic events at 2-years. Use of anticoagulants in AF after ACS 
is still suboptimal. 
Keywords: acute coronary syndromes, antithrombotic therapy, atrial fibrillation, 
registry 
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Introduction 
Known or new-onset atrial fibrillation (AF) is a relatively common comorbid condition 
or complication in patients with acute coronary syndromes (ACS), and is observed in 
4–12% of ACS patients.1, 2 The existence of prior AF is associated with increased 
morbidity and mortality on top of the risk incurred by ACS, both in hospital and up to 
1-year post-discharge,2-4 but any impact on outcomes beyond 1-year has not yet 
been prospectively elucidated.1 
 It should perhaps be noted that this study was performed before many of 
the newer and more effective antithrombotic agents became available e.g., 
ticagrelor. In 2006, ESC guidelines recommended antithrombotic therapy to prevent 
thromboembolism for most patients with AF, specifically, anticoagulation with a 
vitamin K antagonist was recommended for patients with more than 1 moderate risk 
factor, combined with low-dose aspirin and/or clopidogrel following percutaneous 
coronary intervention (PCI).5 In contrast, recent guidelines recommend 
revascularization therapies and use of intensive antithrombotic therapies in AF 
patients, including triple therapy with a combination of dual antiplatelet therapy 
(DAPT) and an oral anticoagulant, particularly those with a CHA2DS2-VASc (Cardiac 
failure, Hypertension, Age ≥75 [doubled], Diabetes, Stroke [doubled] – VAScular 
disease, Age 65–74 and Sex category [female]) score of ≥2, with the key aim of 
stroke prevention.6-9 However, the risk of bleeding is increased considerably with 
triple therapy compared with DAPT.10, 11 Since both ischaemic and bleeding 
complications are associated with impaired prognosis, the difficulty lies in achieving 
a balance between reducing the risk of cardiovascular events and increasing the risk 
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of bleeding, with consideration given to multiple factors, including individual patient 
characteristics, choice and duration of therapy and, where relevant, choice of stent. 
The long-tErm follow-uP of antithrombotic management patterns In acute 
CORonary syndrome patients (EPICOR) registry (NCT01171404) was primarily 
designed to describe the frequency of different antithrombotic management patterns 
(AMPs) in a real-life setting in patients surviving hospitalization for an ACS, with a 2-
year follow-up period.12 The aim of this post-hoc analysis was to determine AMPs 
and long-term (2-year) post-discharge mortality and cardiovascular event rates in 
ACS patients with or without AF, including known prior AF or new-onset, in-hospital 
AF, in a real-life setting. 
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Methods 
Study design 
EPICOR was a multinational, observational, prospective cohort study conducted in 
555 hospitals in 20 countries across four regions of the world: Eastern, Northern and 
Southern Europe, and Latin America. Full details of the EPICOR rationale and study 
design, definitions, in-hospital and long-term results have been published 
previously.12-14 Briefly, patients aged at least 18 years who survived hospitalization 
for confirmed ST-elevation myocardial infarction (STEMI), or non-ST-segment 
elevation-ACS (NSTE-ACS, including NSTEMI and unstable angina) were enrolled 
at discharge from hospital and followed up for 2 years. Exclusion criteria included 
‘secondary’ ACS (precipitated by or occurring as a complication of surgery, trauma, 
PCI, or other reasons), any serious comorbidities considered likely to limit life 
expectancy to less than 6 months, and prior enrolment in EPICOR.  
Events were adjudicated by the local investigators. Data were collected using 
electronic case report forms, including details of acute-phase (from symptom onset 
to discharge) and long-term management and outcomes, the latter by telephone 
follow-up every 3 months by trained interviewers. All patients were required to have 
been hospitalized within 24-h of symptom onset, and to provide written informed 
consent. The final protocol was approved by the ethics committees of participating 
centres in accordance with each country’s local regulations. 
Objectives 
The primary objective of the EPICOR registry was to evaluate acute and long-term 
AMPs in ACS patients in a real-life setting. A full list of secondary endpoints has 
been reported previously, and included evaluation of in-hospital and post-discharge 
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clinical outcomes (ischaemic and bleeding events).12 The objectives of this post-hoc 
analysis were to compare patient characteristics, in-hospital and discharge AMPs, 
and clinical outcomes (mortality, cardiovascular events and bleeding events) at 2-
years according to the presence or absence of AF, including known prior AF and 
new-onset AF Figure S1 (supplementary material). Known prior AF included all AF 
diagnosed before admission for the index event, even if it was no longer present, 
and AF that was ongoing at admission. New-onset AF included only AF that started 
during the index hospitalization; patients with prior AF (no longer ongoing) that re-
emerged during the index hospitalization were included in the prior AF group rather 
than the new-onset AF group.  
Statistical analysis 
Comparisons of patient characteristics, in-hospital and discharge antithrombotic 
management and ischaemic and bleeding events between patients with and without 
AF were performed with Pearson’s chi-squared test. 
Multivariable logistic regression analysis was performed to assess the effect 
of baseline patient characteristics on in-hospital intervention, antithrombotic 
medication and cardiac complications. Univariable and multivariable Cox 
proportional hazards models were used to assess the effect of prior, new-onset or 
any AF on either 2-year mortality or a composite endpoint of death, non-fatal 
myocardial infarction (MI), or non-fatal stroke within 2 years. For each model, the 
assumption of proportional hazards was tested using Schoenfeld residuals. The 
baseline variables adjusted for in the multivariable models are those previously 
found to be predictive of mortality when the EPICOR dataset was used to create a 
risk score15: age (per 10 years), left ventricular ejection fraction (LVEF) <40% and 
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<30%, EuroQol 5 dimensions (EQ-5D) score (per unit), serum creatinine (per unit 
≥1.2 mg/dL), other cardiac complications in hospital (MI/recurrent ischemia, 
cardiogenic shock, heart failure, or any other arrhythmia), blood glucose ≥160 
mg/dL, chronic obstructive pulmonary disease, male gender, diagnosis (STEMI vs. 
NSTE-ACS), PCI or coronary artery bypass graft (CABG), haemoglobin <13 g/dL, 
peripheral vascular disease, on diuretics at discharge, and region (Eastern Europe, 
Latin America, Northern Europe, Southern Europe). 
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Results 
Patients 
A total of 10,568 ACS patients were enrolled in EPICOR between 1 September 2010 
and 31 March 2011, of whom 497 (4.7%) had known prior AF at baseline and 382 
(3.6%) had new-onset AF during the index event Figure S1 (supplementary 
material), (Table 1). Data were missing for 134 patients (117 for prior AF and 21 for 
new-onset AF, including four patients with missing data for both categories of AF). 
Patients with any AF were more likely than those without to have a diagnosis of 
NSTE-ACS (64.3% vs. 35.7%), were older (mean 70.5% vs. 60.9 years; age ≥65 
years 70.9% vs. 37.3%), were less often men (66.9% vs. 75.8%), had higher 
proportions of LVEF <30% (5.5% vs. 2.2%), serum creatinine ≥1.2 mg/dL (34.8% vs. 
20.3%), and blood glucose ≥160 mg/dL (28.8% vs. 22.6%), and a higher mean 
CHA2DS2-VASc score (3.0 vs. 1.7) (all p < 0.001) (Table 1). Patients with AF were 
also more likely to have comorbidities, such as peripheral vascular disease (10.2% 
vs. 4.6%), and chronic obstructive pulmonary disease (11.4% vs. 6.1%) (both 
p < 0.001) (Table 1), and a poorer quality of life, as indicated by higher EQ-5D 
scores (p < 0.001).  
Management 
Despite an apparently higher cardiovascular risk level than patients without AF, 
those with AF significantly less frequently underwent coronary angiography (p < 
0.05) (Table 1), or were treated with PCI (p < 0.001) Figure S2 (supplementary 
material). In contrast, patients with new-onset AF were more likely to undergo CABG 
(p < 0.001) Figure S2 (supplementary material). The overall revascularization rate 
(PCI and CABG combined) for patients with versus without AF was 58.6% versus 
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68.7%. The differences for AF versus no-AF patients undergoing PCI or CABG 
remained significant (p < 0.001) after adjustment for baseline variables Table S1 
(supplementary material). 
The overall in-hospital use of antiplatelet agents was high, but patients with 
AF were less likely than those without to receive most of them, including aspirin 
(90.9% vs. 94.4%), prasugrel (3.2% vs. 8.0%), and glycoprotein IIb/IIIa inhibitors 
(12.4% vs. 17.1%) (all p < 0.001). There was no significant difference in the use of 
clopidogrel in patients with or without any AF (85.0% vs. 87.1%, p = 0.082), but both 
DAPT and triple antiplatelet therapy (TAPT) were used less frequently in AF patients 
(82.3% vs. 89.9%, p < 0.001; and 11.7% vs. 16.2%, respectively; p = 0.001) (Table 
1). In most cases, the differences derived mainly from the population with prior AF. 
Conversely, patients with AF were more likely to receive low molecular weight 
heparin (LMWH) (51.1% vs. 46.9%, p = 0.017) as due to greater use in patients with 
new-onset AF (60.2%), and more were treated with oral anticoagulants 
(warfarin/acenocoumarol in most cases: 27.3% vs. 2.0%; p < 0.001). The use of 
fibrinolysis was low, particularly in AF patients (5.6% vs. 8.6%; p < 0.001). After 
adjustment for baseline characteristics, significance disappeared for many of the AF 
versus no-AF differences, but remained for prasugrel (p = 0.002), DAPT (p = 0.006), 
LMWH (p = 0.028) and oral anticoagulants (p < 0.001) Table S1 (supplementary 
material). It should be noted that the results for some parameters (e.g. use of aspirin 
for management of the index event) were significant but in opposite directions for 
prior and new-onset AF, effectively cancelling out the effect for any AF.  
A similar pattern was observed for discharge medication, with fewer AF than 
non-AF patients receiving DAPT (71.6% vs. 89.5%, p < 0.0001) Figure S3A 
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(supplementary material), and more AF patients discharged on oral anticoagulants, 
albeit only one-third of them (35.0% vs. 2.5%, p < 0.0001), most of whom were on 
warfarin/acenocoumarol. Among AF patients, oral anticoagulant use at discharge 
was low despite many (90% of prior AF patients) having a CHADs2VASc score ≥2, 
but was higher in those with prior AF than new-onset AF (42.9% vs. 24.9%). These 
included a relatively small percentage of AF patients who were discharged on an oral 
anticoagulant plus a single antiplatelet (13.5% vs. 0.8% for any vs. no AF), most of 
which was in patients with prior AF (17.3%). Therapy consisting of DAPT plus an oral 
anticoagulant, was more frequently given at discharge in AF versus no-AF patients, 
including prior AF (19.9% vs. 2.0%), new-onset AF (14.1% vs. 2.4%) and any AF 
(17.0% vs. 1.5%). By the end of follow-up, the differences in management pattern 
persisted, with over half of all AF and no-AF patients remaining on DAPT at 2-years 
(55.6% vs. 60.6%), and 17.2% of any AF patients on TAPT (Figure 1) and Figure 
S3B (supplementary material). Use of any oral anticoagulant in AF patients declined 
over time; to 42.1% of prior AF patients, and 23.3% of those with new-onset AF, at 2-
years. 
Cardiovascular and bleeding complications in-hospital 
Patients with any AF were significantly more likely to have other in-hospital 
cardiovascular or bleeding complications than those without AF (31.2% vs. 16.1%, 
p < 0.001), including MI/recurrent ischaemia (7.7% vs. 5.5%), cardiogenic shock 
(2.3% vs. 0.9%), heart failure (16.0% vs. 4.8%), any other arrhythmia (8.9% vs. 
4.7%), stroke (0.7% vs. 0.2%) and bleeding (5.8% vs. 3.0%) (Table 2). The overall 
rate of these complications was significantly different for prior versus no prior AF 
(26.8% vs. 16.9%) and new-onset versus no new-onset AF (37.0% vs. 16.7%) (both 
p < 0.001). However, the higher in-hospital complication rates in AF patients derived 
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from those with new-onset rather than prior AF. After adjustment for baseline 
variables, the differences remained significant but marginally less so for prior versus 
no prior AF (p = 0.034) Table S2 (supplementary material). 
Two-year clinical outcomes 
At 2-years of follow-up post-discharge, the proportion of patients who had died was 
significantly higher among ACS patients with prior AF versus no prior AF (15.1% vs. 
5.2%), new-onset AF (9.9% vs. 5.6%), or any AF (12.9% vs. 5.0%) (all p < 0.0001) 
(Figure 2) and Figure S4 (supplementary material). Significant differences in the 
same direction were also observed for the composite endpoint of death, non-fatal MI 
or non-fatal stroke, and for bleeding events (all p < 0.0001 except new-onset vs. no 
new-onset AF bleeding events, p = 0.0001). The number of patients with the 
individual components of non-fatal MI and non-fatal stroke was small, and no 
statistical comparisons were performed, but non-fatal MI was numerically less 
frequent in patients with than without new-onset AF (1.0% vs. 1.9%), whereas non-
fatal stroke was more frequent in all categories of patients with AF.  
Univariable and multivariable analysis 
Uni- and multivariable analysis provided significance for many variables, including for 
mortality and the composite endpoint: 
Mortality 
On univariable analysis, the hazard ratio (HR [95% confidence interval (CI)]) for risk 
of death was significantly higher in patients with prior AF, new-onset AF or any AF 
(3.15 [2.48, 4.02], 1.89 [1.36, 2.63] and 2.77 [2.25, 3.40], respectively; p ≤ 0.0001 in 
each case). On multivariable analysis, after adjusting for other variables known to be 
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predictive of mortality, the HR (95% CI) for risk of death decreased in each case but 
remained significant for prior AF and any AF, but not for new-onset AF, 1.48 (1.14, 
1.90), p = 0.003; 1.32 (1.06, 1.64), p = 0.013; and 1.03 (0.73, 1.44), p = 0.88, 
respectively Tables S3–S5 (supplementary material).  
Among the multiple variables analysed, it was found that patients with prior 
AF were significantly less likely to receive PCI or CABG during index hospitalization 
(relative risk, RR [95% CI], 0.74 [0.68, 0.81], p < 0.001) Table S1 (supplementary 
material), and removal of adjustment for PCI/CABG increased the overall HR 
estimate from 1.48 to 1.54 (95% CI 1.19, 1.99; p = 0.001). This suggests that the risk 
of death in patients with prior AF is further increased by the reduced likelihood of 
invasive intervention during the index hospitalization.  
Composite of death, non-fatal MI or non-fatal stroke  
Prior AF, new-onset AF and any AF were also associated with significantly higher 
rates of the composite endpoint of death, non-fatal MI and non-fatal stroke on 
univariable analysis, HR (95% CI); 2.90 (2.34, 3.60), p < 0.0001; 1.67 (1.24, 2.24), p 
= 0.0008; and 2.48 (2.05, 2.99), p < 0.0001, respectively. As for the endpoint of 
death alone, the HR (95% CI) for the composite endpoint remained significant on 
multivariable analysis for prior AF (1.46 [1.16, 1.83], p = 0.001) and any AF (1.28 
[1.06, 1.56], p = 0.012), but not for new-onset AF (0.98 [0.73, 1.33], p = 0.92) Tables 
S6–S8 (supplementary material). Again, removal of PCI/CABG from the adjustment 
for prior AF increased the estimated HR (95% CI) to 1.51 (1.21, 1.90); p = 0.0004.  
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Discussion 
The results of this analysis of 2-year follow-up data from the EPICOR registry 
demonstrate that AF, particularly prior AF, is a major contributor to in-hospital 
cardiac complications, and increased risk of mortality and cardiovascular events in 
the long term. Furthermore, despite guideline recommendations,6, 8, 10 fewer AF 
patients underwent PCI (52% compared with 67% of non-AF patients), only 72% 
were discharged on DAPT (compared with 90% of non-AF patients), and only 35% 
were discharged on oral anticoagulant therapy (43% with prior AF and 25% with 
new-onset AF) even though the majority had a CHADs2VASc score ≥2. At the end of 
follow-up, use of any oral anticoagulant in AF patients had declined to 34%. While 
triple therapy was used in 17% of AF patients at discharge, combination therapy with 
an oral anticoagulant and a single antiplatelet was used in 14%. 
 Consistent findings were reported in a recent European Heart Rhythm 
Association (EHRA) survey, an internet questionnaire-based study, in which only 15 
(41%) of 37 centres routinely administered triple therapy to all AF patients following 
PCI, and 22 (59%) centres used them in AF patients with moderate-to-high 
thromboembolic risk.11 Over 90% of centres surveyed used a combination of aspirin, 
clopidogrel and warfarin. 
Despite the relatively low use of oral anticoagulants (OACs) at discharge in 
EPICOR, there was a significantly greater long-term risk of bleeding events in AF 
patients, both prior and new-onset. Stroke was reported infrequently during follow-
up, but was numerically more likely to occur in patients with any category of AF. The 
majority were discharged on warfarin/acenocoumarol, whereas evidence indicates 
that the newer, non-vitamin K oral anticoagulants (NOACs) have a more favourable 
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risk profile.16 However, given recent reports of lower bleeding rates with NOACs 
compared with vitamin K antagonists, when used in combination with antiplatelet 
agents after an ACS and/or PCI, it can be speculated that current OAC use will be 
higher.17, 18 
 Additionally, multivariable analysis of the data from EPICOR showed that 
adjustment for other variables resulted in important changes in terms of the 
cardiovascular risk associated with AF. Multivariable analysis reconfirmed the 
increased risk of events in ACS patients with AF; that is, after adjustment for other 
baseline predictor variables, prior AF remained associated with worse outcomes of 
both death (HR 1.48, 95% CI 1.14, 1.90; p = 0.003), and the composite endpoint of 
death, non-fatal MI or non-fatal stroke (HR 1.46, 95% CI 1.16, 1.83; p = 0.001). 
These results suggest that prior AF, but not new-onset AF, is an independent 
predictor of increased risk of both mortality and the composite endpoint of death, 
non-fatal MI or non-fatal stroke. The lower risk of clinical events associated with new-
onset AF might be related not only to the lower risk profile but in addition to the fact 
that some patients may have had AF only in the acute phase related to the ischemia, 
and maintained thereafter in sinus rhythm.  
Limitations of this study include being a sub-study, potential bias or 
inaccuracy in reporting of the follow-up data due to the 3-month interval between 
telephone calls, and changes in availability of antithrombotic drugs over the study 
duration, and investigator-led adjudication of clinical events. Also, as the population 
included only hospital survivors, there is no means of determining whether AF is 
associated with early, in-hospital, mortality. Finally, the analysis did not account for 
cardiac rhythm at hospital discharge. It may well be that, in patients with new-onset 
16 
AF, outcomes differ in those with AF persisting at discharge versus those in sinus 
rhythm at discharge. 
In conclusion, in clinical practice, patients with ACS and AF (known prior and 
new-onset) are treated less frequently with revascularization therapies, and more 
than half do not receive oral anticoagulation at discharge, with a decline in use over 
time. They also experience a high event rate during long-term follow-up, with 
increased mortality, and cardiovascular and bleeding events compared with ACS 
patients without AF. Multivariable analysis indicates that prior AF is an independent 
predictor of both mortality and the composite endpoint of death, non-fatal MI or non-
fatal stroke during the first 2 years after discharge, whereas new-onset AF is not. 
Every effort should be made to increase the rate of guideline-adherent therapies in 
these high-risk patients after ACS. The adoption of a more personalized 
management approach, addressing individual patient risk factors, as well as closer 
follow-up may also help to improve long-term outcomes in patients with AF.  
17 
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Table 1. Patient demographics, disease parameters and management; AF versus no AF, prior or new-onset. 
 
Prior AF 
Y / N 
(n = 497 / 9954) 
RRc; p-value 
New-onset AF 
Y / N 
(n = 382 / 10,165) 
RRc; p-value 
Any AF 
Y / N 
(n = 879 / 9565) 
RRc; p-value 
Demographics and disease parameters 
Diagnosis       
 STEMI 129 (26.0) / 4762 (47.8) 
< 0.001 
185 (48.4) / 4748 (46.7) 
0.51 
314 (35.7) / 4572 (47.8) 
< 0.001 
 NSTE-ACS 368 (74.0) / 5192 (52.2) 197 (51.6) / 5417 (53.3) 565 (64.3) / 4993 (52.2) 
Age, years; mean (SD) 72.5 (9.9) / 61.2 (12.1) < 0.001 67.9 (11.5) / 61.5 (12.2) < 0.001 70.5 (10.9) / 60.9 (12.1) < 0.001 
Age group       
 <65 113 (22.7) / 6146 (61.8) 
< 0.001 
143 (37.4) / 6166 (60.7) 
< 0.001 
256 (29.1) / 5997 (62.7) 
< 0.001  65–74 149(30.0) / 2229 (22.4) 115 (30.1) / 2285 (22.5) 264 (30.0) / 2111 (22.1) 
 >74 235 (47.3) / 1578 (15.9) 124 (32.5) / 1713 (16.9) 359 (40.8) / 1456 (15.2) 
Sex       
 Men 301 (60.6) / 7541 (75.8) 
< 0.001 
287 (75.1) / 7619 (75.0) 
0.94 
588 (66.9) / 7250 (75.8) 
0.001 
 Women 196 (39.4) / 2413 (24.2) 95 (24.9) / 2546 (25.0) 291 (33.1) / 2315 (24.2) 
LVEF       
 ≥40% 375 (83.7) / 8238 (89.8) 
< 0.001 
283 (80.6) / 8379 (89.7) 
<0.001 
658 (82.4) / 7946 (90.1) 
< 0.001 
 <40% 52 (11.6) / 725 (7.9) 45 (12.8) / 743 (8.0) 97 (12.1) / 681 (7.7) 
24 
 <30% 21 (4.7) / 212 (2.2) 23 (6.6) / 216 (2.3) 44 (5.5) / 191 (2.2) 
COPD 59 (12.0) / 616 (6.2) < 0.001 40 (10.6) / 642 (6.4) 0.001 99 (11.4) / 575 (6.1) < 0.001 
PVD  57 (11.8) / 470 (4.8) < 0.001 30 (8.1) / 498 (5.0) 0.007 87 (10.2) / 439 (4.6) < 0.001 
On diureticsa  219 (44.5) / 1713 (17.3) < 0.001 136 (35.8) / 1826 (18.0) < 0.001 355 (40.7) / 1578 (16.7) < 0.001 
CHA2DS2-VASc score; 
mean (SD) 
3.4 (1.6) / 1.7 (1.5) < 0.001 2.4 (1.6) / 1.8 (1.6) < 0.001 3.0 (1.7) / 1.7 (1.5) < 0.001 
CHA2DS2-VASc score      
 
 
< 0.001 
0 12 (2.5) / 2249 (23.2) 
< 0.001 
39 (10.7) / 2219 (22.6) 
< 0.001 
51 (6.0) / 2207 (23.7) 
1 47 (9.8) / 2796 (28.8) 86 (23.6) / 2759 (28.1) 133 (15.8) / 2709 (29.0) 
2 80 (16.7) / 1984 (20.4) 76 (20.9) / 1983 (20.2) 156 (18.5) / 1902 (20.4) 
3 110 (23.0) / 1354 (14.0) 72 (19.8) / 1388 (14.1) 182 (21.6) / 1277 (13.7) 
4 111 (23.2) / 822 (8.5) 53 (14.6) / 881 (9.0) 164 (19.5) / 768 (8.2) 
5–9 119 (24.8) / 500 (5.2) 38 (10.4) / 584 (6.0) 157 (18.6) / 463 (5.0) 
In-hospital management 
Fibrinolysis 16 (1.7) / 931 (9.4) 0.35; < 0.001 33 (8.6) / 921 (9.1) 0.95; 0.77 49 (5.6) / 896 (9.4) 0.60; < 0.001   <0.001 
Antiplatelets       
Aspirin 434 (87.3) / 9404 (94.5) 0.92; < 0.001 365 (95.5) / 9557 (94.0) 1.02; 0.15 799 (90.9) / 9032 (94.4) 0.96; 0.001 
Clopidogrel 410 (82.5) / 8667 (87.1) 0.95; 0.010 337 (88.2) / 8820 (86.8) 1.02; 0.39 747 (85.0) / 8327 (87.1) 0.98; 0.10 
Prasugrel 13 (2.6) / 783 (7.9) 0.33; < 0.001 15 (3.9) / 787 (7.7) 0.51; 0.008 28 (3.2) / 765 (8.0) 0.40; < 0.001 
25 
GP IIb/IIIa inhibitor 42 (8.5) / 1705 (17.1) 0.49; < 0.001 67 (17.5) / 1691 (16.6) 1.05; 0.64 109 (12.4) / 1638 (17.1) 0.72; < 0.001 
DAPT 383 (77.1) / 8950 (89.9) 0.86; < 0.001 340 (89.0) / 9067 (89.2) 1.00; 0.91 723 (82.3) / 8603 (89.9) 0.91; < 0.001 
Aspirin+clopidogrel 372 (74.8) / 8385 (84.2) 0.89; < 0.001 327 (85.6) / 8501 (83.6) 1.02; 0.28 699 (79.5) / 8054 (84.2) 0.94; 0.001 
TAPTb 39 (7.8) / 1612 (16.2) 0.48; < 0.001 64 (16.8) / 1598 (15.7) 1.07; 0.58 103 (11.7) / 1548 (16.2) 0.72; 0.001 
Anticoagulants       
UFH 143 (28.8) / 3527 (35.4) 0.81; 0.004 124 (32.5) / 3567 (35.1) 0.93; 0.30 267 (30.4) / 3400 (35.5) 0.85; 0.003 
LMWH 219 (44.1) / 4713 (47.3) 0.93; 0.16 230 (60.2) / 4744 (46.7) 1.29; < 0.001 449 (51.1) / 4483 (46.9) 1.09; 0.013 
Fondaparinux 45 (9.1) / 1051 (10.6) 0.86; 0.29 53 (13.9) / 1049 (10.3) 1.34; 0.024 98 (11.1) / 998 (10.4) 1.07; 0.51 
Bivalirudin 2 (0.4) / 162 (1.6) 0.25; 0.049 3 (0.8) / 162 (1.6) 0.49; 0.22 5 (0.6) / 159 (1.7) 0.34; 0.018 
Oral anticoagulants 167 (33.6) / 257 (2.6) 13.01; < 0.001 73 (19.1) / 358 (3.5) 5.42; < 0.001 240 (27.3) / 189 (2.0) 13.82; < 0.001 
Warfarin/ 
acenocoumarol 
166 (33.4) / 255 (2.6) 13.04; < 0.001 73 (19.1) / 355 (3.5) 5.47; < 0.001 239 (27.2) / 187 (2.0) 13.91; < 0.001 
Dabigatran 1 (0.2) / 2 (0.02) 10.01; 0.060 0 (0.0) / 3 (0.03) – ; – 1 (0.1) / 2 (0.02) 5.44; 0.17 
Intervention       
Coronary 
angiography 
356 (71.8) / 8202 (82.6) 0.87; <0.001 297 (77.7) / 8339 (82.3) 0.95; 0.042 653 (74.4) / 7896 (82.8) 0.90; <0.001 
PCI 245 (49.3) / 6586 (66.2) 0.75; < 0.001 213 (55.8) / 6674 (65.7) 0.85; < 0.001 458 (52.1) / 6367 (66.6) 0.78; < 0.001 
CABG 8 (1.6) / 256 (2.6) 0.63; 0.19 49 (12.8) / 217 (2.1) 6.01; < 0.001 57 (6.5) / 205 (2.1) 3.03; 0.001 
Medication at discharge <0.001  <0.001  <0.001 
No antiplatelet 5 (1.0) / 41 (0.4)  4 (1.0) / 42 (0.4)  9 (1.0) / 37 (0.4)  
26 
       
SAPT 30 (6.0) / 901 (9.1)  49 (12.8) / 900 (8.9)  79 (9.0) / 851 (8.9)  
DAPT 248 (49.9) / 8657 (87.0)  233 (61.0) / 8743 (86.0)  481 (54.7) / 8416 (88.0)  
Oral anticoagulants 214 (43.1) / 353 (3.5)  96 (25.1) / 478 (4.7)  310 (35.3) / 260 (2.7)  
All data are for evaluable patients only, and values are n (%) of patients unless otherwise indicated.  
AF: atrial fibrillation; CHA2DS2-VASc: Cardiac failure, Hypertension, Age ≥75 [doubled], Diabetes, Stroke [doubled] – VAScular disease, Age 65–74 and Sex category [female]; 
CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; DAPT: dual antiplatelet therapy; GP: glycoprotein; LMWH: low molecular weight heparin; 
LVEF: left ventricular ejection fraction; NSTE-ACS: non-ST-segment elevation-acute coronary syndrome; PCI: percutaneous coronary intervention; PVD: peripheral vascular 
disease; RR: relative risk; STEMI: ST-segment elevation myocardial infarction; TAPT: triple antiplatelet therapy; UFH: unfractionated heparin; Y / N: yes / no. 
p-values are for difference between patients with or without AF in each case. 
aAt discharge. 
bAspirin plus either clopidogrel or prasugrel, and a GP IIb/IIIa inhibitor. 
cApplies to in-hospital management only. 
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Table 2. Other in-hospital cardiovascular and bleeding complications. 
 
Prior AF 
Y (n = 497) / 
N (n = 9954) 
 
New-onset AF 
Y (n = 382) / 
N (n = 10 165) 
 
Any AF 
Y (n = 879) / 
N (n = 9565) 
 
RR p RR p RR p 
None 358 (73.2) / 8195 (83.1) 
1.59 < 0.001 
235 (63.0) / 8390 (83.3) 
2.21 < 0.001 
593 (68.8) / 7964 (83.9) 
1.94 < 0.001 
Any of the following 131 (26.8) / 1666 (16.9) 138 (37.0) / 1688 (16.7) 269 (31.2) / 1527 (16.1) 
MI/recurrent 
ischaemia 
33 (6.7) / 554 (5.6) 1.19 0.31 34 (9.1) / 565 (5.6) 1.63 0.004 67 (7.7) / 519 (5.5) 1.41 0.005 
Cardiogenic shock 5 (1.0) / 99 (1.0) 1.01 0.97 15 (3.9) / 93 (0.9) 4.29 < 0.001 20 (2.3) / 83 (0.9) 2.63 < 0.001 
Heart failure 71 (14.4) / 528 (5.3) 2.70 < 0.001 69 (18.1) / 547 (5.4) 3.35 < 0.001 140 (16.0) / 460 (4.8) 3.32 < 0.001 
Any other arrhythmia 28 (5.7) / 500 (5.0) 1.13 0.53 50 (13.2) / 486 (4.8) 2.76 < 0.001 78 (8.9) / 450 (4.7) 1.90 < 0.001 
Stroke 1 (0.2) / 26 (0.3) 0.77 0.80 5 (1.3) / 22 (0.2) 6.04 < 0.001 6 (0.7) / 21 (0.2) 3.11 0.014 
Bleeding 22 (4.4) / 321 (3.2) 1.37 0.14 29 (7.6) / 313 (3.1) 2.46 < 0.001 51 (5.8) / 291 (3.0) 1.91 < 0.001 
AF: atrial fibrillation; MI: myocardial infarction; RR: relative risk. 
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Figure 1. Change in antithrombotic medication over time; any AF and no AF. 
 
Differences in management pattern persisted during follow-up, with over half of all AF and no-AF patients 
remaining on DAPT at 2-years. 
AF: atrial fibrillation; DAPT: dual antiplatelet therapy; FU: follow up; OAC: oral anticoagulant. 
*Excluding patients who died or were lost to follow-up at each time point.  
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Figure 2. Clinical outcomes at 2-years: composite of death/non-fatal MI/stroke, the 
three individual components, and bleeding events. 
 
At 2-years, rates of mortality, composite endpoint, and bleeding events were significantly higher among acute 
coronary syndrome patients with AF versus no AF, whether prior, new-onset, or any AF. 
AF: atrial fibrillation; MI: myocardial infarction. 
*p < 0.0001 AF versus no AF for death, death/non-fatal MI/stroke, and bleeding events. 
†p < 0.0001 AF versus no AF for death, death/non-fatal MI/non-fatal stroke, and p = 0.0001 for bleeding events. 
Figure Click here to download Figure Figure 1.tif 
Figure Click here to download Figure Figure 2.tif 
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